A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol
A phase 2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) is a phase 2 interventional study registered as NCT06099782 by Merck Sharp & Dohme LLC, with 147 participants enrolled, started 2023-12-26 and due to reach its primary completion in 2025-04-09. Interventions recorded: Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab. Conditions listed: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
Shares Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of NDI 1150-101 in Patients With Solid Tumors
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Shares Renal cell carcinoma, Melanoma, Pembrolizumab, Small-cell lung cancer.
- TrialSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P
Shares Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
Shares Merck & Co. (MSD), Melanoma, Pembrolizumab.
- TrialA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (
Shares Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Beta-only IL-2 ImmunoTherapY Study
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Merck & Co. (MSD), Melanoma, Pembrolizumab, Non-small-cell lung cancer.